Plain-English translation of NCT06675201 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach called NeoDC-Vac combined with immune checkpoint inhibitors (ICIs) to help prevent esophageal cancer from returning after you've completed your initial chemotherapy and radiation. The personalized vaccine is created specifically for your own tumor, using genetic information from a tissue sample taken at the start of the study. The goal is to see if this combination treatment helps you stay cancer-free longer and improves your overall survival.
Esophageal cancer that cannot be surgically removed often comes back even after chemotherapy and radiation. Researchers believe that training your immune system to recognize and fight any remaining cancer cells — using a vaccine tailored to your tumor — might help prevent recurrence and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You will have an endoscopy at West China Hospital to confirm your diagnosis and provide a tissue sample for genetic testing to create your personalized vaccine. You'll then be randomly assigned to receive either the vaccine plus monthly immune-boosting infusions, or just the immune-boosting infusions alone. If you receive the vaccine, you'll get five injections under your skin during the first two months, then one injection every four weeks for a total of one year. Throughout the year, you'll also receive monthly intravenous infusions of the immune medication and have regular follow-up visits to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China